welcome
Investor's Business Daily

Investor's Business Daily

Health

Health

Eli Lilly stock soars after late-stage weight-loss trial meets goals

Investor's Business Daily
Summary
Nutrition label

70% Informative

Eli Lilly's orforglipron lowered blood sugar and body weight in patients with Type 2 diabetes.

The trials are part of a tight competition to move the booming weight-loss drug business to oral pills.

Pfizer scrapped development of its oral weight loss pill, danuglipron, after one patient experienced potential drug-induced liver injury.

VR Score

68

Informative language

68

Neutral language

50

Article tone

formal

Language

English

Language complexity

40

Offensive language

not offensive

Hate speech

not hateful

Attention-grabbing headline

detected

Known propaganda techniques

not detected

Time-value

short-lived

Source diversity

1

Affiliate links

no affiliate links